Marker Therapeutics, Inc.Marker Therapeutics, Inc.Marker Therapeutics, Inc.

Marker Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪36.86 M‬USD
−1.93USD
‪−16.97 M‬USD
‪3.31 M‬USD
‪6.43 M‬
Beta (1Y)
1.38

About Marker Therapeutics, Inc.

CEO
Juan F. Vera
Headquarters
Houston
Employees (FY)
8
Founded
1991
ISIN
US57055L2060
FIGI
BBG000GMZP09
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of MRKR is 4.14 USD — it has increased by 0.97% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Marker Therapeutics, Inc. stocks are traded under the ticker MRKR.
Marker Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
MRKR stock is 5.19% volatile and has beta coefficient of 1.38. Check out the list of the most volatile stocks — is Marker Therapeutics, Inc. there?
MRKR earnings for the last quarter are 0.29 USD per share, whereas the estimation was −0.80 USD resulting in a 136.25% surprise. The estimated earnings for the next quarter are −0.90 USD per share. See more details about Marker Therapeutics, Inc. earnings.
Marker Therapeutics, Inc. revenue for the last quarter amounts to ‪790.51 K‬ USD despite the estimated figure of ‪2.50 M‬ USD. In the next quarter revenue is expected to reach ‪400.00 K‬ USD.
Yes, you can track Marker Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
MRKR stock has fallen by 10.39% compared to the previous week, the month change is a 8.61% fall, over the last year Marker Therapeutics, Inc. has showed a 333.24% increase.
MRKR net income for the last quarter is ‪−2.74 M‬ USD, while the quarter before that showed ‪−2.98 M‬ USD of net income which accounts for 8.11% change. Track more Marker Therapeutics, Inc. financial stats to get the full picture.
Today Marker Therapeutics, Inc. has the market capitalization of ‪36.86 M‬, it has increased by 8.03% over the last week.
No, MRKR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MRKR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Marker Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
MRKR reached its all-time high on Apr 15, 2003 with the price of 1080432.00 USD, and its all-time low was 0.67 USD and was reached on Mar 31, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 22, 2024, the company has 8.00 employees. See our rating of the largest employees — is Marker Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Marker Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Marker Therapeutics, Inc. stock shows the sell signal. See more of Marker Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Marker Therapeutics, Inc. EBITDA is ‪−13.45 M‬ USD, and current EBITDA margin is −440.37%. See more stats in Marker Therapeutics, Inc. financial statements.